 Connection
Vernon Holers to Complement Inactivating Agents
This is a "connection" page, showing publications Vernon Holers has written about Complement Inactivating Agents.
|
|
| |
Connection Strength |
|
 |
|
 |
| |
4.120 |
|
|
|
-
Liu F, Wawersik S, Tomlinson S, Thurman JM, Holers VM. Tissue-targeted regulators of complement for amelioration of human disease: rationale and novel therapeutic strategies. J Immunol. 2025 Sep 01; 214(9):2138-2149.
Score: 0.900
-
Holers VM. Systemic lupus erythematosus as the paradigm for understanding the complex immune relationships and therapeutic opportunities for targeting complement in autoimmune diseases. Immunobiology. 2025 05; 230(3):152915.
Score: 0.883
-
Thurman JM, Frazer-Abel A, Holers VM. The Evolving Landscape for Complement Therapeutics in Rheumatic and Autoimmune Diseases. Arthritis Rheumatol. 2017 11; 69(11):2102-2113.
Score: 0.522
-
Holers VM, Tomlinson S, Kulik L, Atkinson C, Rohrer B, Banda N, Thurman JM. New therapeutic and diagnostic opportunities for injured tissue-specific targeting of complement inhibitors and imaging modalities. Semin Immunol. 2016 06; 28(3):260-7.
Score: 0.475
-
Holers VM, Rohrer B, Tomlinson S. CR2-mediated targeting of complement inhibitors: bench-to-bedside using a novel strategy for site-specific complement modulation. Adv Exp Med Biol. 2013; 735:137-54.
Score: 0.374
-
Rohrer B, Long Q, Coughlin B, Renner B, Huang Y, Kunchithapautham K, Ferreira VP, Pangburn MK, Gilkeson GS, Thurman JM, Tomlinson S, Holers VM. A targeted inhibitor of the complement alternative pathway reduces RPE injury and angiogenesis in models of age-related macular degeneration. Adv Exp Med Biol. 2010; 703:137-49.
Score: 0.304
-
Li Y, Jacques S, Gaikwad H, Nebbia M, Banda NK, Holers VM, Tomlinson SA, Scheinman RI, Monte A, Saba L, Lasda E, Hasselberth J, Busquet N, Zelek WM, Moghimi SM, Simberg D. Enhanced immunocompatibility and hemocompatibility of nanomedicines across multiple species using complement pathway inhibitors. Sci Adv. 2025 Jul 11; 11(28):eadw1731.
Score: 0.223
-
Guaschino V, Santarsiero D, Gastoldi S, Thurman JM, Holers VM, Violette SM, Liu F, Fahnoe KC, Guarinoni C, Benigni A, Remuzzi G, Noris M, Aiello S. C3d-targeted complement inhibitors to correct complement dysregulation in aHUS patients. Front Immunol. 2025; 16:1620996.
Score: 0.222
-
Rich MC, Keene CN, Neher MD, Johnson K, Yu ZX, Ganivet A, Holers VM, Stahel PF. Site-targeted complement inhibition by a complement receptor 2-conjugated inhibitor (mTT30) ameliorates post-injury neuropathology in mouse brains. Neurosci Lett. 2016 Mar 23; 617:188-94.
Score: 0.116
-
Thorgersen EB, Ghebremariam YT, Thurman JM, Fung M, Nielsen EW, Holers VM, Kotwal GJ, Mollnes TE. Candidate inhibitors of porcine complement. Mol Immunol. 2007 Mar; 44(8):1827-34.
Score: 0.061
-
Li C, Patel K, Tu Z, Yang X, Kulik L, Alawieh A, Allen P, Cheng Q, Wallace C, Kilkenny J, Kwon J, Gibney B, Cantu E, Sharma A, Pipkin M, Machuca T, Emtiazjoo A, Goddard M, Holers VM, Nadig S, Christie J, Tomlinson S, Atkinson C. A novel injury site-natural antibody targeted complement inhibitor protects against lung transplant injury. Am J Transplant. 2021 06; 21(6):2067-2078.
Score: 0.041
|
Connection Strength
The connection strength for concepts is the sum of the scores for each matching publication.
Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.
|